MedTrace Logo

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

NCT04868708 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-03-04

No results posted yet for this study

Summary

This is a multicenter, open-label, phase II clinical study conducted in China. All subjects will receive AK104 in combination with standard treatment regimens or AK104 alone. The primary end point is safety. The secondary end point is efficacy.

Conditions

  • Recurrent or Metastatic Cervical Cancer

Interventions

BIOLOGICAL

AK104

Subjects will receive AK104 intravenously.

BIOLOGICAL

Bevacizumab

Subjects will receive Bevacizumab intravenously.

DRUG

Paclitaxel

Subjects will receive Paclitaxel intravenously.

DRUG

Cisplatin or Carboplatin

Subjects will receive Cisplatin or Carboplatin intravenously.

Sponsors & Collaborators

Principal Investigators

  • Jing Wang, MD · Hunan Cancer Hospital

  • Hanmei Lou · Zhejiang Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2024-02-28
Completion
2024-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04868708 on ClinicalTrials.gov